retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Agonism Based Therapies for Obesity | Current Cardiovascular Risk Reports Triple G Agonists – Retatrutide.
Description
Plasma insulin response to oral and intravenous glucose administration
The antiemetic actions of GIP receptor agonism
These second order effects will become more far reaching as insurance coverage becomes wider for these drugs - this will be the differentiator between the risk/reward being better on the first-order beneficiaries (LLY and NVO) and the second-order plays like short bariatric surgery/sleep apnea/gyms/fast food & CPG
Gromada J, Franklin I, Wollheim CB
